Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed of assemblies of misfolded cellular prion protein (PrP) 1 . A novel PrP variant, G127V, was under positive evolutionary selection during the epidemic of kuru-an acquired prion disease epidemic of the Fore population in Papua New Guinea-and appeared to provide strong protection against disease in the heterozygous state 2 . Here we have investigated the protective role of this variant and its interaction with the common, worldwide M129V PrP polymorphism. V127 was seen exclusively on a M129 PRNP allele. We demonstrate that transgenic mice expressing both variant and wild-type human PrP are completely resistant to both kuru and classical Creutzfeldt-Jakob disease (CJD) prions (which are closely similar) but can be infected with variant CJD prions, a human prion strain resulting from exposure to bovine spongiform encephalopathy prions to which the Fore were not exposed. Notably, mice expressing only PrP V127 were completely resistant to all prion strains, demonstrating a different molecular mechanism to M129V, which provides its relative protection against classical CJD and kuru in the heterozygous state. Indeed, this single amino acid substitution (GRV) at a residue invariant in vertebrate evolution is as protective as deletion of the protein. Further study in transgenic mice expressing different ratios of variant and wild-type PrP indicates that not only is PrP V127 completely refractory to prion conversion but acts as a potent dose-dependent inhibitor of wild-type prion propagation.
Prions cause fatal neurodegenerative conditions such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and CJD in humans 1 . The fundamental molecular process-seeded propagation of assemblies of misfolded host protein-is increasingly recognized as being of importance in all the major human neurodegenerative diseases 3 . There is a common polymorphism, present worldwide, in the substrate protein in human prion disease, human prion protein (PrP), where either methionine (M) or valine (V) is present at residue 129. MV heterozygosity provides relative protection against acquired, sporadic and some inherited prion diseases [4] [5] [6] and may have been selected during the evolution of modern humans by ancestral prion disease epidemics 7 . This protective effect is thought to relate to inhibition of homotypic protein-protein interactions 5, 8 , although residue 129 also influences the propagation of particular prion strains via conformational selection 9, 10 . Heterozygosity at another polymorphism, E219K, also provides resistance to CJD in Japan 11 .
Kuru was a devastating epidemic prion disease transmitted by endocannibalism and restricted to a remote area in Papua New Guinea. We reported a novel PrP variant (G127V) among unaffected individuals that appeared to be a resistance factor selected by the epidemic and unique to this region 2 . Given the proximity to residue 129, we considered that it may have a similar action to M129V; that is, blocking homotypic interactions and exerting its protective effect only in the heterozygous state. No PRNP codon 127VV homozygotes were identified in the kuru-exposed population and V127 was always seen on an M129 allele 2 . We therefore generated multiple lines of transgenic mice, expressing only human PrP (HuPrP) on a congenic FVB/N PrP null (Prnp o/o ) background, to investigate whether G127V was indeed protective and whether this protection was dependent on heterozygosity or was an intrinsic property of the variant protein. Furthermore, we investigated its interaction with the residue 129 polymorphism.
We generated two lines of transgenic mice homozygous for HuPrP V127: Tg(HuPrP V127M129/V127M129 Prnp o/o )-183 (hereafter referred to as V127M129 Tg183) and Tg(HuPrP V127M129/ V127M129 Prnp o/o )-190 (V127M129 Tg190). PrP expression levels in homozygotes as compared to pooled normal human brain were twofold for V127M129 Tg183 and onefold for V127M129 Tg190. G127V heterozygous mice were derived by crossing these lines with FVB-congenic versions of Tg35 mice homozygous for HuPrP G127M129 (refs 12-15) or Tg152 mice homozygous for HuPrP G127V129 (refs 15-19) , designated Tg(HuPrP G127M129/ G127M129 Prnp o/o )-35c (G127M129 Tg35c) and Tg(HuPrP G127V129/G127V129 Prnp o/o )-152c (G127V129 Tg152c), respectively. G127M129 Tg35c and G127V129 Tg152c mice express wildtype HuPrP at two and six times, respectively, as compared to pooled normal human brain (Table 1) . Extended Data Fig. 1 shows relative PrP C expression levels in all transgenic mice used in this study.
All transgenic lines were challenged by intracerebral prion inoculation from well-characterized and previously transmitted human prion disease cases including all three PRNP codon 129 genotypes and comprising four cases of kuru, twelve cases of classical CJD and two cases of variant CJD (vCJD).
Heterozygous HuPrP G127M129/V127M129 mice (Tg35c 3 Tg183 and Tg35c 3 Tg190) ( Table 1) , which have the genotype associated with disease resistance in the kuru-exposed human population, were completely resistant to all four kuru isolates (which included all three PRNP codon 129 genotypes and two molecular strain types) ( Fig. 1a and Table 2a ), while mice expressing wild-type HuPrP G127M129/G127M129 (Tg35c) ( Fig. 1a and Table 2a ) or G127V129/G127V129 (Tg152c) ( Table 2b ) were fully susceptible with 100% attack rates. This is consistent with the population genetic data suggesting kuru resistance of G127V individuals. We have previously reported that prion strains seen in kuru brain are indistinguishable from those seen in classical CJD patients 19 . Similarly, none of the four classical CJD isolates from patients of the PRNP genotype 129MM transmitted to either line of G127M129/V127M129 mice (Table 2a and Fig. 1b ), while all four transmitted uniformly to Tg35c mice expressing wild-type HuPrP ( Fig. 1b and Table 2a ). Remarkably, however, some (,10%) G127M129/V127M129 mice developed clinical disease, and a larger number (,70%) showed evidence of subclinical infection (positive PrP immunohistochemistry and/or western blot for PrP Sc ), on challenge with vCJD prions (Table 2d and Extended Data Fig. 2 ). vCJD is a novel BSE-derived prion strain 17, 20, 21 to which the population in the kuru-affected area of Papua New Guinea were not exposed.
The key question with respect to whether the protective effect of V127 is conferred via a similar mechanism to the M129V polymorphism was addressed by challenge of mice homozygous for HuPrP V127M129. While mice homozygous for wild-type HuPrP G127M129 or G127V129 are both highly susceptible to CJD prions, mice homozygous for HuPrP V127M129 were completely resistant to all 18 human prion disease isolates, including vCJD prions, with no clinical transmissions or evidence of subclinical infection ( Fig. 1a , b, Table 3 and Extended Data Fig. 3 ).
We also challenged mice heterozygous at both residues 127 and 129 of HuPrP (G127V129/V127M129) produced by crossing Tg183 or Tg190 mice with Tg152c mice (Tables 1 and 2b). The higher level of expression of HuPrP V129 in Tg152c mice as compared to the other lines meant that there was a marked difference in the ratio of expression of the variant (V127M129) and wild-type (G127V129) HuPrP in these crosses (Table 1) . While Tg183 and Tg35c had closely similar levels of expression of V127M129 and G127M129 HuPrP, respectively, such that the Tg35c 3 Tg183 cross closely modelled the human PRNP G127V genotype, the expression ratios of wild-type G127V129 to variant V127M129 HuPrP were approximately 6:1 and 3:1 for the Tg152c 3 Tg190 and Tg152c 3 Tg183 crosses, respectively (Table 1 and Extended Data Figs 1 and 4). Interestingly, in these crosses some transmissions of kuru and classical CJD prions were seen (Table 2b and Extended Data Figs 4 and 5). In the Tg152c 3 Tg183 crosses, with a threefold excess of wild-type PrP, subclinical infections were seen with four out of the twelve isolates used, and one kuru isolate (I10336) was associated with clinical disease (Table 2b ). With the Tg152c 3 Tg190 crosses, however, showing a sixfold excess of wild-type PrP, transmissions were seen from all isolates, with the majority resulting in clinical disease (Table 2b) .
To investigate further the effect of HuPrP V127 on prion propagation, we compared hemizygous Tg(HuPrP G127V129 Prnp o/o )-152c mice with the Tg152c 3 Tg183 and Tg152c 3 Tg190 crosses (Table  2c ). The hemizygous line was challenged with two classical CJD and one kuru isolate that had resulted in a 100% attack rate in both crosses. Again, 100% attack rates were seen for all three isolates but the incubation periods were significantly shorter (P , 0.0001; Table 2c ) in the absence of HuPrP V127 than in either cross. These data, together with comparison of the two crosses themselves (Table 2b) , are consistent with a dominant-negative effect of HuPrP V127 expression. Although dominant-negative inhibition has been reported for other natural polymorphic residues of mammalian PrP in transgenic mice [22] [23] [24] , none has shown complete prevention of prion conversion when expressed at a 1:1 ratio with wild-type PrP. Dominant-negative effects on yeast prion propagation have also been reported 25 .
Our transgenic modelling of the HuPrP G127V polymorphism demonstrates that it confers strong protection against prion disease in the heterozygous state. However, most importantly, the molecular basis of this effect is clearly distinct from that proposed for the wellestablished HuPrP M129V polymorphism, which is protective against developing sporadic CJD only in the heterozygous state: inhibition of homotypic protein-protein interactions during the process of prion 
WT{ G127 allele expression level ( 3)

Variant{ V127 allele expression level ( 3)
PrP ratio G127:V127 Tg35c  G127M129/G127M129  2  2  --Tg152c  G127V129/G127V129  6  6  --Tg183  V127M129/V127M129  2  -2  -Tg190 V127M129 G127M129 is a wild-type human allele, and the V127M129 allele is seen only in humans from the kuruexposed population of Papua New Guinea. Attack rate reports the total of clinically affected and subclinically infected mice as a proportion of the number of inoculated mice after prolonged (.600 days) post-inoculation periods. Primary prion transmission data are reported in Tables 2 and 3 . { Attack rate is defined as the total number of both clinically affected and subclinically infected mice as a proportion of the total number of inoculated mice. Subclinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. Incubation periods are reported for clinically affected mice in days; where n $ 3 the mean 6 s.e.m. is reported with the number of mice contributing to the mean shown in parentheses, otherwise individual incubation times are given. In groups where no clinical transmission of prion disease was observed, the attack rate represents subclinical infection only and the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as .x-y days.
Parental lines
{ Mean incubation periods for all three isolates are significantly lower in Tg152c hemizygotes than in Tg190 3 Tg152c heterozygotes (P , 0.0001; two-tailed unpaired t-test). { Attack rate is defined as the total of clinically affected and subclinically infected mice as a proportion of the number of inoculated mice. Subclinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. As no clinical transmission of prion disease was observed, the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as .x-y days. 
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propagation. Here we demonstrate that HuPrP V127 is intrinsically resistant to prion conversion and indeed capable of inhibiting propagation of wild-type prions in a dose-dependent manner. Mice expressing only HuPrP V127 appear to be as resistant to prion disease as PrP null mice 26 , and understanding the structural basis of this effect may therefore provide critical insight into the molecular mechanism of mammalian prion propagation. At its height, when first recognized by Western medicine in 1957, kuru was a devastating epidemic largely affecting women and children and killing up to 2% of the population annually in some villages. Some villages became largely devoid of young women of childbearing age. While collapse of the Fore population was prevented by cessation of endocannibalism in the late 1950s, which interrupted the route of transmission and led to a gradual decline in incidence 27 , our data suggest that if transmission had continued the epicentre of the affected region might have been repopulated with kuru-resistant individuals as a population genetic response to the epidemic. Understanding the structural basis of why HuPrP V127 is unable to propagate prions of multiple strain types may provide key insights into prion propagation and the development of rational therapeutics.
METHODS
No statistical methods were used to predetermine sample size. Ethics statement. Storage and biochemical analyses of post-mortem human brain samples and transmission studies to mice were performed with written informed consent from patients with capacity to give consent. Where patients were unable to give informed consent, assent was obtained from their relatives in accordance with UK legislation and Codes of Practice. Samples were stored and used in accordance with the Human Tissue Authority Codes of Practice and in line with the requirements of the Human Tissue Authority licence held by UCL Institute of Neurology. This study was performed with approval from the Medical Research Advisory Committee of the Government of Papua New Guinea, the National Hospital for Neurology and Neurosurgery and the UCL Institute of Neurology Joint Research Ethics Committee (now National Research Ethics Service Committee, London -Queen Square); REC references: 03/N036, 03/N038 and 03/N133. Work with mice was performed under approval and licence granted by the UK Home Office (Animals (Scientific Procedures) Act 1986); Project Licence number 70/6454 which conformed to University College London institutional and ARRIVE guidelines (http://www.nc3rs.org.uk/ARRIVE/). Generation of transgenic mice. The 759-bp human PrP ORF was amplified by PCR with pfu polymerase from genomic DNA prepared from the brain of a patient with the V127 polymorphism on the M129 allele, using forward primer 59-GTCGACCAGTCATTATGGCGAACCTT-39 and reverse primer 59-CTCGAGAAGACCTTCCTCATCCCACT-39. Restriction sites SalI (GTCGAC) and Xho I (CTCGAG) (underlined) were introduced in the forward and reverse primers respectively for cloning. The blunt-ended PCR fragment generated by pfu polymerase was subcloned into SmaI-digested pSP72 vector and sequenced to ensure that no spurious alterations had been introduced by the PCR and to confirm the presence of V127 and M129 polymorphisms matching the patient DNA template. The amplified human PrP ORF with the confirmed polymorphisms was then isolated by SalI and Xho I digestion. Subsequent subcloning into the SalI site of the cosmid vector SHaCosTt, packaging and preparation of high quality DNA of the Not I transgene insert was as previously reported 12 . Microinjection of the purified Not I DNA fragment was carried out according to standard protocol into single cell eggs of Prnp null mice which had been backcrossed onto an FVB/N genetic background. Genotyping was performed by PCR and PrP expression levels estimated by western blot analysis as previously reported 12, 29 . Two homozygous lines were established for variant HuPrP V127M129 described as Tg(HuPrP V127M129/V127M129 Prnp o/o )-183 (V127M129 Tg183) and Tg(HuPrP V127M129/V127M129 Prnp o/o )-190 (V127M129 Tg190), with PrP C expression levels of 2 and 1 times, respectively, that of pooled 10% (w/v) normal human brain homogenate (Table 1) . FVB-congenic versions of Tg35 mice homozygous for HuPrP G127M129 (refs 12-15) and Tg152 mice homozygous for HuPrP G127V129 (refs 15-19) were used as wild-type human PrP-expressing controls, designated Tg(HuPrP G127M129/G127M129 Prnp o/o )-35c (G127M129 Tg35c) and Tg(HuPrP G127V129/G127V129 Prnp o/o )-152c (G127V129 Tg152c), respectively. The PRNP codon 127-129 genotypes and relative expression levels of wild-type and variant PrP in the parental transgenic lines and in the F 1 crosses are shown in Table 1 . Transmission studies. Strict biosafety protocols were followed. Inocula were prepared, using disposable equipment for each inoculum, in a microbiological containment level 3 laboratory and inoculations performed within a class 1 microbiological safety cabinet as described previously 12, 19 . Ten mice per group of control G127M129 Tg35c and G127V129 Tg152c lines and 15 per group of newly generated V127M129 Tg183 and V127M129 Tg190 lines and their respective crosses with Tg35c and Tg152c were inoculated (see below) with human brain homogenates from neuropathologically confirmed patients comprising four kuru cases, eight sporadic CJD cases, four iatrogenic CJD cases and two cases of vCJD. The genotype of each mouse was confirmed by PCR of ear punch DNA before inclusion and all mice were uniquely identified by sub-cutaneous transponders. Disposable cages were used and all cage lids and water bottles were also uniquely identified by transponder and remained with each cage of mice throughout the incubation period. Care of the mice was according to institutional guidelines. Mice (female, aged 6-8 weeks) were randomly assigned to experimental groups and anaesthetized with a mixture of halothane and O 2 , and intracerebrally inoculated into the right parietal lobe with 30 ml of a 1% (w/v) brain homogenate prepared in Dulbecco's phosphate buffered saline lacking Ca 21 or Mg 21 ions (D-PBS). All mice were thereafter examined daily for early indicators of clinical prion disease including piloerection, sustained erect ears, intermittent generalized tremor, unsustained hunched posture, rigid tail, mild loss of coordination, and clasping hind legs when lifted by the tail. Definite diagnosis of clinical prion disease (triggering experimental end point) was reached if mice exhibited any two early indicator signs in addition to one confirmatory sign, or any two confirmatory signs. The confirmatory signs included ataxia, impairment of righting reflex, dragging of hind limbs, sustained hunched posture, or prominent abnormal breathing. Mice were killed (by CO 2 asphyxiation) if they exhibited any signs of distress or once a diagnosis of prion disease was established. At post-mortem, brains from inoculated mice were removed, divided sagittally with half frozen and half fixed in 10% buffered formol saline. Subsequent immunohistochemical or biochemical investigations were performed blind to sample provenance. Neuropathology and immunohistochemistry. Fixed brain was immersed in 98% formic acid for 1 h and paraffin wax embedded. Serial sections of 4 mm thickness were pre-treated by boiling for 10 min in a low ionic strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) before exposure to 98% formic acid for 5 min. Abnormal PrP accumulation was examined using anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) on a Ventana automated immunohistochemical staining machine (Ventana Medical Systems Inc., Tucson, Arizona) using proprietary secondary detection reagents (Ventana Medical Systems Inc.) before development with 393 diaminobenzedine tetrachloride as the chromogen 30 . Harris haematoxylin and eosin staining was done by conventional methods. Appropriate controls were used throughout. Immunoblotting. Preparation of brain homogenates (10% (w/v) in D-PBS), proteinase K digestion (75 mg ml 21 for 1 h at 37 uC) and subsequent immunoblotting was performed as described previously 28, 30 . Blots were probed with anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) in conjunction with an anti-mouse IgG-alkaline phosphatase conjugate and development in chemiluminescent substrate (CDP-Star; Tropix Inc.). Primary screening of brain homogenates was performed blind to sample identity. LETTER RESEARCH
